Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals

Hepatitis C virus (HCV) infection is a major public health concern. New antiviral drugs are required urgently to complement and improve the efficacy of current chemotherapies. Molecules specifically targeting viral enzymes are the most attractive in terms of drug development and are, therefore, the...

Cijeli opis

Bibliografski detalji
Glavni autori: Chapel, C, Zitzmann, N, Zoulim, F, Durantel, D
Format: Journal article
Izdano: Future Medicine 2006
_version_ 1826287633415798784
author Chapel, C
Zitzmann, N
Zoulim, F
Durantel, D
author_facet Chapel, C
Zitzmann, N
Zoulim, F
Durantel, D
author_sort Chapel, C
collection OXFORD
description Hepatitis C virus (HCV) infection is a major public health concern. New antiviral drugs are required urgently to complement and improve the efficacy of current chemotherapies. Molecules specifically targeting viral enzymes are the most attractive in terms of drug development and are, therefore, the most studied. However, an antiviral strategy based uniquely on the utilization of this type of target is expected to encounter problems caused by the emergence of viral escape mutants as has already been widely described for HIV and hepatitis B virus. HCV morphogenesis and viral entry represent interesting, and yet unexploited, novel molecular targets. Inhibitors of morphogenesis have recently been identified and studied in different virus–cell systems. Some of these are currently being evaluated in clinical trials against HCV. This review focuses on HCV morphogenesis, viral entry and inhibition and presents clinical development perspectives of this new generation of antivirals.
first_indexed 2024-03-07T02:01:36Z
format Journal article
id oxford-uuid:9d8c9404-80aa-4240-a74e-cce68827dba6
institution University of Oxford
last_indexed 2024-03-07T02:01:36Z
publishDate 2006
publisher Future Medicine
record_format dspace
spelling oxford-uuid:9d8c9404-80aa-4240-a74e-cce68827dba62022-03-27T00:43:53ZVirus morphogenesis and viral entry as alternative targets for novel hepatitis C antiviralsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9d8c9404-80aa-4240-a74e-cce68827dba6Symplectic Elements at OxfordFuture Medicine2006Chapel, CZitzmann, NZoulim, FDurantel, DHepatitis C virus (HCV) infection is a major public health concern. New antiviral drugs are required urgently to complement and improve the efficacy of current chemotherapies. Molecules specifically targeting viral enzymes are the most attractive in terms of drug development and are, therefore, the most studied. However, an antiviral strategy based uniquely on the utilization of this type of target is expected to encounter problems caused by the emergence of viral escape mutants as has already been widely described for HIV and hepatitis B virus. HCV morphogenesis and viral entry represent interesting, and yet unexploited, novel molecular targets. Inhibitors of morphogenesis have recently been identified and studied in different virus–cell systems. Some of these are currently being evaluated in clinical trials against HCV. This review focuses on HCV morphogenesis, viral entry and inhibition and presents clinical development perspectives of this new generation of antivirals.
spellingShingle Chapel, C
Zitzmann, N
Zoulim, F
Durantel, D
Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals
title Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals
title_full Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals
title_fullStr Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals
title_full_unstemmed Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals
title_short Virus morphogenesis and viral entry as alternative targets for novel hepatitis C antivirals
title_sort virus morphogenesis and viral entry as alternative targets for novel hepatitis c antivirals
work_keys_str_mv AT chapelc virusmorphogenesisandviralentryasalternativetargetsfornovelhepatitiscantivirals
AT zitzmannn virusmorphogenesisandviralentryasalternativetargetsfornovelhepatitiscantivirals
AT zoulimf virusmorphogenesisandviralentryasalternativetargetsfornovelhepatitiscantivirals
AT duranteld virusmorphogenesisandviralentryasalternativetargetsfornovelhepatitiscantivirals